Phase II US trial of liposomal docetaxel [ATI 1123] in pancreatic cancer
Latest Information Update: 20 Jan 2020
At a glance
- Drugs Docetaxel (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 15 Feb 2017 This trial was being conducted by Azaya Therapeutics . The Company has now been acquired by Cytori Therapeutics, according to a Cytori Therapeuticsmedia release.
- 18 Sep 2013 New trial record